Previous Close | 56.26 |
Open | 56.45 |
Bid | 0.00 x 900 |
Ask | 57.88 x 1000 |
Day's Range | 56.14 - 56.51 |
52 Week Range | 31.45 - 68.08 |
Volume | |
Avg. Volume | 2,807,831 |
Market Cap | 10.208B |
Beta (5Y Monthly) | 1.20 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -7.18 |
Earnings Date | May 17, 2024 - May 21, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 57.32 |
Novo Nordisk's head of development on Friday told Reuters he was very comfortable the drugmaker would be able to launch the pill version of its experimental weight loss drug amycretin this decade. Research head Lange said the drugmaker could launch the pill version of its experimental weight loss drug amycretin this decade. It expects both new experimental obesity drugs cagrisema and amycretin to lead to greater weight loss than its hugely popular Wegovy.
SOMERSET, N.J., March 07, 2024--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, has today published its fiscal 2023 Corporate Responsibility Report, highlighting positive progress across every pillar of Catalent’s corporate responsibility strategy – People, Environment, and Community. The report also outlines the company’s future commitments as it progresses its mission to help people lead better and healthier lives.
Catalent (CTLT) reports lower revenues in Biologics segments in its second-quarter fiscal 2024, resulting in overall soft performance.